Plain-English translation of NCT07733674 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new imaging drug called 203Pb-RMX-VH-PIB to see how it works in patients with glioblastoma (a serious brain tumor) or pancreatic cancer. You would receive a single injection of this medication, followed by several imaging scans that show where the drug goes in your body and how much radiation different organs receive. The goal is to understand if this new imaging tool can help doctors better see and treat these cancers.
Doctors need better ways to see where tumors are located and understand how new imaging treatments behave in the body. This medication has the potential to help, and this early-stage study will gather the safety and effectiveness information needed before it can be used more widely.
You likely qualify if…
You likely don't qualify if…
You would come to the study center to receive a single injection of the new imaging medication into your vein. Over the following hours or days, you would have several whole-body imaging scans (SPECT/CT) to show where the medication travels in your body. Before and after the injection, the study team will check your vital signs, draw blood and urine samples, and perform a heart rhythm test (ECG). The research staff will watch closely for any side effects for 30 days after your injection and will stay in touch to make sure you're doing well.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
United States